Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Market Insight, Epidemiology and Market Forecast - 2034

Executive Summary

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Disease Understanding and Treatment Algorithm:

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Overview
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare neurological disorder. It is an acquired peripheral neuropathy due to an autoimmune attack of peripheral nerve myelin. Myelin is the main target of the condition, in which patients present with weakness, numbness, and sensory ataxia (symptoms of large myelinated fiber dysfunction). A great deal of evidence, such as the finding of inflammation at the site of the lesion, response to immunomodulatory treatment and possibly the presence of autoantibodies against myelin antigens. The inflammation of the peripheral nervous system damages the myelin sheaths that insulate nerve fibers. CIDP usually spares the nerves that supply muscles of respiration and the autonomic nerves that control the bladder, bowel, and circulation. The disorder sometimes also called chronic relapsing polyneuropathy.

The disease often presents with symptoms that include tingling or numbness (beginning in the toes and fingers), weakness of the arms and legs, loss of deep tendon reflexes (areflexia), fatigue, and abnormal sensations. It can occur at any age and in both genders, CIDP is more common in young adults, and men more so than women. This condition is treatable for relatively long periods (months to years) in the majority of patients. CIDP usually presents in the “classical” form as the symmetrical disorder with proximal and distal weakness but also can manifest as a variety of other subtypes that can be multifocal or selectively involve sensory or motor nerve fibers.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Diagnosis and Treatment:

It covers the details of conventional and current medical therapies and diagnosis available in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market report gives a thorough understanding of CIDP symptoms by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides CIDP symptoms of treatment algorithms and treatment guidelines for CIDP symptoms in the US, Europe, and Japan.

The EFNS/PNS diagnostic criteria can address most of the diagnostic pitfalls and able to distinguish the different sub-types. According to EFNS/PNS guidelines, misdiagnosis is common in CIDP, especially in the atypical subtype. Electrophysiologic testing, the sensitivity of which is improved by testing more than 4 nerves, is necessary to confirm the diagnosis. The testing of 3 limbs may improve the diagnostic certainty of electrophysiologic testing. High-resolution ultrasound is a readily available tool that can be used at the bedside. Recent study results have demonstrated the potential utility of measuring abnormal nerve enlargement, both in the brachial plexus and proximal median nerve segments in the arm, with high-resolution ultrasound in the differential diagnosis of CIDP.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology:

The CIDP symptoms epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings:

The total diagnosed prevalent cases of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) patients 7MM during the study period, i.e. 2017-2030.

The disease epidemiology covered in the report provides historical as well as forecasted CIDP symptoms epidemiology segmented as the Total prevalence of CIDP, Gender-Specific cases of CIDP, Clinical Subtype specific cases of CIDP, Age-Specific cases of CIDP. The report includes the prevalent scenario of CIDP symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology:

The epidemiology segment also provides the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The total prevalent population of CIDP in 7MM countries was estimated to be 44,700 in 2017.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Chapters:

The drug chapter segment of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) report encloses the detailed analysis of CIDP marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Marketed Drugs:

Privigen: CSL Behring
Privigen is indicated for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to improve neuromuscular disability and impairment. Privigen is the first and only, ready-to-use, sterile, room-temperature stored, liquid, polyvalent IVIG stabilized with L-proline. The drug acts as an immunostimulant. It is approved in the US, Europe, and Japan for the treatment of CIDP in adults to improve neuromuscular disability and impairment.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Emerging Drugs:

GGS-CIDP: Teijin Pharma

GGS-CIDP is an intravenous, freeze-dried sulfonated human normal immunoglobulin which reported to shows high efficacy in restoring the lost muscle strength by its immune regulatory action of inhibiting the inflammation of the peripheral nerves; the drug thus offers promise as a treatment that will restore lost muscle strength. The molecule has completed the Phase III developmental studies for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and filed NDA for manufacturing and marketing approval of GGS-CIDP.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Outlook:

The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the publisher, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market in 7MM is expected to change in the study period 2017–2030.

The current therapeutic landscape in the 7MM divided into conventional therapies such as Corticosteroids, Plasma Exchange (PE), and Intravenous immunoglobulin (IVIG) which are also considered as the first line of therapy. In Corticosteroids therapy, mostly Prednisone and Dexamethasone are indicated among them. It induces a therapeutic response after 2 months and maximal improvement is observed after a long period with gradual incremental of dose. It has been in the therapeutic use for CIDP as of the first reporting of cases.

Plasma Exchange (PE) is an invasive therapy that requires well-trained personnel at specialized centers. It demonstrated short-term efficacy in the early days formerly may deteriorate within weeks to months after treatment.

Intravenous immunoglobulin (IVIG) has been used as the first-line therapy for CIDP over the past two decades with established efficacy and recommended to be offered as the long-term treatment. Though, the therapy with IVIG is expensive and time-consuming, and may have limited availability in some circumstances; the patient reported Improvement usually within a few weeks.

Key Findings:

This section includes a glimpse of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market in 7MM. The market size of CIDP in the seven major markets is expected to be USD 968 million in 2017.

The United States Market Outlook:

This section provides the total Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market Size and market Size by therapies in the United States.

The United States accounts for the highest market size of CIDP in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan. Even though the IVIG has proven efficacy, the therapies are associated with the high cost and frequent adverse effects.

EU-5 Countries: Market Outlook:

The total Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market Size and market Size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Currently, used IVIG products are licensed for CIDP either purely nationally or via the MR-procedure in certain EU states or, in one case, centrally in the entire EU. The Tegeline of the LFB has been got approval from the France authorities. The Polyvalent immunoglobulins of the Kedrion Biopharma were approved by the Italian authorities to include in the CIDP treatment regimens. The approval of the SCIG paved the way for patient compliance therapies shortly. Consequently, the market share is expected to increase during the forecast period [2020–2030]

Japan Market Outlook:

The total Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market Size and market Size by therapies in Japan are also mentioned.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drugs Uptake:

This section focusses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2017–2030. The analysis covers Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pipeline Development Activities:

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) key players involved in developing targeted therapeutics.

Major players include Teijin Pharma, Octapharma, Shire/ Takeda, MedDay Pharmaceuticals, UCB Biopharma, argenx, Momenta Pharmaceuticals, Pfizer and others. GGS-CIDP (Teijin Pharma), NewGam (Octapharm) and HyQvia (Shire/Takeda) are the late-stage immunoglobin therapies.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing and patent details for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) emerging therapies.

Reimbursement Scenario in CIDP:

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, the publisher takes reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business & price strategy.

Commercial insurance companies typically reimburse for IG to treat many diseases regardless of whether they are designated as FDA-approved for IG therapy. Medicare Part B will reimburse IG for most diagnosis codes in the physician office or hospital outpatient setting. Both Typical and Atypical CIDP are covered under the FDA approved (Diagnosis Code - 357.81) condition to get coverage for IG therapy.

KOL - Views

To keep up with current market trends, the publisher takes KOLs and SME’s opinion working in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) domain through primary research to fill the data gaps and validate the secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

The publisher performs Competitive & Market Intelligence analysis of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market by using various Competitive Intelligence tools that includes – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

• CSL Behring
• Grifols/Kedrion Biopharma
• Nihon Pharmaceutical
• LFB
• Teijin Pharma
• OctaPharma
• Shire/ Takeda
• UCB Biopharma
• MedDay Pharmaceuticals
• LFB
• GeNeuro Pharmaceuticals
• Pfizer
• argenx
• Momenta Pharmaceuticals